大黄素抑制人高转移巨细胞肺癌PG细胞的肿瘤转移相关性质  

Inhibitory Effect of Emodin on Metastasis Associated Properties of PG Cells from a Human highly Metastatic Giant Lung Carcinoma Cell Line

作　　者：王心华[1] 甄永苏[1] 

机构地区：[1]中国医学科学院

出　　处：《癌症》2001年第8期789-793,共5页Chinese Journal of Cancer

基　　金：国家自然科学基金项目No:39870941

摘　　要：目的:研究大黄素对人高转移巨细胞肺癌PG细胞转移相关性质的影响。方法:MTT法检测大黄素对多种恶性肿瘤细胞的增殖抑制作用;BoydenChamber法检测大黄素对PG细胞侵袭能力的影响;明胶酶谱法(Zymography)检测大黄素对PG细胞Ⅳ型胶原酶分泌的影响;流式细胞术检测大黄素对PG细胞周期的影响Westernblot法检测大黄素作用后PG细胞周期相关蛋白的表达。结果:大黄素可抑制来源于不同组织多种肿瘤细胞的增殖,其IC50值在15～70μmol/L。40μmol/L和80μmol/L大黄素处理PG细胞24h,可使细胞侵袭能力分别降低到对照组的76.9%和57.4%,同时可使细胞MMP2和MMP9的分泌量显著下降,大黄素对PG细胞同基底膜的粘附能力没有明显影响。20μmol/L和40μmol/L大黄素作用于PG细胞24h后,可使细胞周期明显阻滞于G2/M期,伴随着S期的相应减少,进一步分析周期相关蛋白的表达,大黄素作用后可使PG细胞cyclinB1蛋白表达明显下降,而对p34cdc2的表达没有明显影响。结论:大黄素能抑制肿瘤细胞转移相关性质,提示其具有抗转移潜能。Objective: To investigate the inhibitory effect of emodin, a herb derived tyrosine kinase inhibitor on metastasis associated properties of PG cells from a human highly metastatic giant lung carcinoma cell line. Methods: MTT assay was used to determine the growth inhibition by emodin in several cultured tumor cells. Invasive capacity was determined by Boyden Chamber assay. Gelatin zymography was performed to detect the secretion of MMP 2 and MMP 9 of PG cells. Flow cytometry and Western blot were applied to detect the change of cell cycle and expression level of cyclinB1 and P34cdc2 proteins. Results: Emodin inhibited the proliferation of several cultured cancer cell lines with IC50 value in range of 15 μmol/L to 70 μmol/L. After 24 h treatment, emodin reduced the invasive capacity and the secretion of MMP 2 and MMP 9 of PG cells, wherease adhesive ability of PG cells to ECM was unaffected. Emodin treatment blocked cell cycle in G2/M phase. Western blot showed down regulation of the expression level of cyclinB1 protein. Conclusion: These results suggest that emodin, which reduces the metastasis associated properties of PG cells, might be potentially useful in cancer therapy.

关 键 词：大黄素 肿瘤侵袭 肿瘤转移 Ⅳ型胶原酶 细胞周期 高转移巨细胞肺癌 PG细胞 

分 类 号：R734.2[医药卫生—肿瘤] R73－37[医药卫生—临床医学]